IONS Ionis Pharmaceuticals
- 40.850
- -0.250-0.61%
- 41.000
- +0.150+0.37%
Ionis Pharmaceuticals News
Ionis Pharmaceuticals Price Target Maintained With a $70.00/Share by RBC Capital
Ionis Pharmaceuticals Analyst Ratings
RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70
Ionis Pharmaceuticals (IONS) Receives a Buy From RBC Capital
BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $68
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Jefferies Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Leerink Partners Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $56
Ionis Pharmaceuticals: A Buy Rating With a Lowered Price Target Amidst Strong Growth Prospects
Top Gap Ups and Downs on Tuesday: AMZN, ORCL, BABA and More
Ionis Pharmaceuticals Down Over 10%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Unusual Options Activity: OVV, KKR and Others Attract Market Bets, OVV V/OI Ratio Reaches 190.3
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
S&P 500 Futures Steady In Premarket Trading; Oracle, Sonoco Products Lead
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $56 From $62
Ionis Shares Drop on Discounted Public Offering
Analysis
Price Target
No Data
No Data